School of Medicine, Pontificial Catholic University of Parana (PUCPR), Curitiba, Brazil.
Research, Development and Medical, Upjohn - A Division of Pfizer, Lima, Peru.
BMC Cardiovasc Disord. 2022 May 21;22(1):237. doi: 10.1186/s12872-022-02669-8.
Non-communicable diseases like systemic arterial hypertension (SAH) and dyslipidemia are poorly studied in terms of patient journey aspects. This semi-systematic review provides evidence synthesis for the management of SAH and dyslipidemia in Brazil and also discusses challenges faced by patients at the local level along with a suggested care approach by local experts.
A semi-systematic review using both structured literature databases (Embase and Medline) and unstructured scientific records (WHO, IPD, MOH and Google) on hypertension and dyslipidemia in the English language from 2010 to 2019 was performed by reviewers. After two-level screening based on pre-defined criteria, patient journey touchpoints and prevalence information were extracted from the included articles. Data gaps were bridged through the insights of local experts.
Prevalence of hypertension and dyslipidemia in Brazil were 23% and 40.8%, respectively. Awareness of dyslipidemia was found in a larger proportion (58.1%) than in SAH (22.2%). Similarly, screening for hypertension (97%) and dyslipidemia (55.4%) were found to be effective, while treatment was (62.9%) and (30.0%) for hypertension and dyslipidemia, respectively.
There were important gaps on patient awareness and treatment of dyslipidemia and hypertension. Limited patient education, regional disease distribution, and treatment allocation, along with limited resources for diagnosis and treatment are the key challenges.
在患者就诊方面,系统性动脉高血压(SAH)和血脂异常等非传染性疾病的研究还很不完善。本半系统综述提供了巴西 SAH 和血脂异常管理的证据综合,还讨论了患者在当地面临的挑战以及当地专家提出的护理方法。
两位评审员使用结构化文献数据库(Embase 和 Medline)和非结构化科学记录(世卫组织、IPD、MOH 和 Google),对 2010 年至 2019 年期间用英语发表的高血压和血脂异常进行半系统综述。根据预先定义的标准进行两级筛选后,从纳入的文章中提取患者就诊接触点和患病率信息。通过当地专家的见解来弥补数据差距。
巴西高血压和血脂异常的患病率分别为 23%和 40.8%。血脂异常的知晓率(58.1%)明显高于 SAH(22.2%)。同样,高血压(97%)和血脂异常(55.4%)的筛查效果良好,而高血压(62.9%)和血脂异常(30.0%)的治疗效果良好。
血脂异常和高血压患者的知晓率和治疗率存在重要差距。患者教育有限、区域疾病分布和治疗分配、以及诊断和治疗资源有限是主要挑战。